









Markets
/
Stocks
/
nasdaq-mreo
/

Mereo BioPharma Group PLC

MREO

1.960USD

-0.040-2.00%

Close 10/14, 16:00（ET）Quotes delayed by 15 min

1.56BMarket Cap

LossP/E TTM



Mereo BioPharma Group PLC

1.960

-0.040-2.00%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mereo BioPharma Group PLC

Currency: USD Updated: 2025-10-13

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mereo BioPharma Group PLC's Score

Industry at a Glance

Industry Ranking

63 / 501

Overall Ranking

143 / 4695

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Strong Buy

Current Rating

7.000

Target Price

+257.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mereo BioPharma Group PLC Highlights

StrengthsRisks

Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.

Overvalued

The company’s latest PE is -30.95, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 109.81M shares, decreasing 6.45% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 59.20K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-10-13

The company's current financial score is 7.58, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Mereo BioPharma Group PLC's Company Valuation

Currency: USD Updated: 2025-10-13

The company’s current valuation score is 7.17, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -30.95, which is -24.00% below the recent high of -23.52 and -196.77% above the recent low of -91.85.

Score

Industry at a Glance

Previous score

7.17

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 63/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-13

The company’s current earnings forecast score is 9.11, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Mereo BioPharma Group PLC is 7.00, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

9.11

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Strong Buy

Current Rating

7.000

Target Price

+250.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

522

Total

Median

Average

Company name

Ratings

Analysts

Mereo BioPharma Group PLC

MREO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

105

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-13

The company’s current price momentum score is 8.54, which is higher than the Biotechnology & Medical Research industry's average of 6.87. Sideways: Currently, the stock price is trading between the resistance level at 2.18 and the support level at 1.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.12

Change

1.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.005

Neutral

RSI(14)

53.278

Neutral

STOCH(KDJ)(9,3,3)

32.337

Sell

ATR(14)

0.112

High Vlolatility

CCI(14)

-9.515

Neutral

Williams %R

44.444

Buy

TRIX(12,20)

0.583

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.996

Sell

MA10

2.008

Sell

MA20

1.925

Buy

MA50

1.796

Buy

MA100

2.055

Sell

MA200

2.360

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-13

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 69.02%, representing a quarter-over-quarter decrease of 11.90%. The largest institutional shareholder is James Simons, holding a total of 1.48M shares, representing 0.93% of shares outstanding, with 21.36% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

17.69M

-22.20%

Rubric Capital Management LP

15.31M

Northpond Ventures, LLC

10.90M

Frazier Life Sciences Management, L.P.

9.44M

+16.98%

Mangrove Partners

8.64M

Deerfield Management Company, L.P.

6.71M

Alkeon Capital Management LLC

4.70M

Rock Springs Capital Management LP

4.47M

-33.20%

683 Capital Management LLC

4.35M

-6.15%

Clearline Capital LP

3.62M

+12.44%

Risk Assessment

Currency: USD Updated: 2025-10-13

The company’s current risk assessment score is 2.99, which is lower than the Biotechnology & Medical Research industry's average of 3.49. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.